The scope of this review includes the multi-targeted biological role of Dehydrozingerone and its analogues since 2016. Each analogue of DZG has a different mode of action that varies with position and type of substitutions. DZG′s full potential can finally be recognized, which can lead to remarkable drug discovery.
Curcumin (Cur) has shown its potential in the treatment of a wide variety of ailments. As a result, several investigations on curcumin have been conducted in vitro, in vivo, and in clinical trials. Regrettably, researchers have largely lost interest in this excellent scaffold due to its chemical instability, poor solubility, and rapid metabolism, which directly affect its pharmacological properties. Alternatively, the researchers are working on it to improve the solubility and biological half-life, it is one of the most researched natural phytochemical to date. Among these, Dehydrozingerone (DZG), a curcumin half structure has garnered considerable research interest due to a wide spectrum of its biological activities. Thus, this study offers insight into the pharmacological activity of modified DZG conjugates (incorporate multiple effective modifications to the various positions), which have been developed since 2016. Additionally, the structure-activity relationship (SAR) of DZG hybrids was illustrated for their specific pharmacological properties. This review presents an update for the scientific community, which could assist in addressing the gaps, challenges and pharmacological aspects of DZG.Zum Volltext